Recombinant Human PD-1 Protein

重组人PD-1蛋白 | 重组人PD-1蛋白

PDCD1_HUMAN | Programmed cell death 1 | Programmed cell death 1 protein | Programmed cell death protein 1 | Protein PD 1 | Protein PD-1 | SLEB2 | Systemic lupus erythematosus susceptibility 2 | CD279 | CD279 antigen | hPD 1 | hPD l | hPD-1 | hSLE1 | PD 1

rp176241-50μg

50μg

无动物源

≥95%(SDS-PAGE)

Purity:≥95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： Programmed Death-1 receptor (PD-1), also known as CD279, is a type I transmembrane protein belonging to the CD28 family of immune regulatory receptors. Other members of this family include CD28, CTLA-4, ICOS, and BTLA. Mature human PD-1 consists of a 148 amino acid (aa) extracellular region (ECD) with one immunoglobulin-like V-type domain, a 24 aa transmembrane domain, and a 95 aa cytoplasmic region. The human PD-1 ECD shares 65% aa sequence identity with the mouse PD-1 ECD. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC). PD‑1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes. Ligation of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion. Thus, the PD-1: PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance. Finally, blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy.

1. Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Toripalimab (anti-PD-1) (Ab182801) with the EC50 of 13.47 ng/mL. 2. Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Zimberelimab (anti-PD-1) (Ab175710) with the EC50 of 19.95 ng/mL. 3. Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Retifanlimab (anti-PD-1) (Ab175644) with the EC50 of 11.39 ng/mL. 4. Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Dostarlimab (anti-PD-1) (Ab175513) with the EC50 of 32.46 ng/mL. 5. Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Spartalizumab (anti-PD-1) (Ab169299) with the EC50 of 12.83 ng/mL. 6. Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Camrelizumab (anti-PD-1) (C412007) with the EC50 of 10.39 ng/mL. 7. Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Sintilimab (anti-PD-1) (Ab169307) with the EC50 of 15.02 ng/mL. 8. Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Cemiplimab (anti-PD-1) (C412010) with the EC50 of 12.82 ng/mL.

重组表达

16.9 kDa

C-His

38.6-44.2 kDa, under reducing conditions; 37.0-43.5 kDa, under non-reducing conditions

HEK293 Accession #: Q15116 | HEK293

<1.0 EU/μg

人(Human)

1-167 aa

MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQHHHHHH

Yes

Yes